TScan Therapeutics

TScan Therapeutics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of TScan Therapeutics (TCRX) as of Oct 18, 2026 is 107.68 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 89.92 % — a change of 19.75% (higher).

FCF Conversion

107.68 %

YoY

19.75%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of TScan Therapeutics is 2025 107.68 % . FCF Conversion Rate (FCF/EBITDA) of TScan Therapeutics was 2024 89.92 % . It decreases by 19.75% higher compared to the previous year.

The TScan Therapeutics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
100.81 USD
Jan 1, 2020
27.79 USD
Jan 1, 2021
120.55 USD
Jan 1, 2022
106.81 USD
Jan 1, 2023
72.30 USD
Jan 1, 2024
89.92 USD
Jan 1, 2025
107.68 USD
The TScan Therapeutics FCF Conversion history
YEARFCF ConversionYoY
107.68 %+19.75%
89.92 %+24.37%
72.30 %-32.31%
106.81 %-11.40%
120.55 %+333.77%
27.79 %-72.43%
100.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

TScan Therapeutics Stock analysis

What does TScan Therapeutics do? TScan Therapeutics Inc., based in Waltham, Massachusetts, is a biotechnology company focused on developing T cell receptor-engineered T cell (TCR-T) therapies for cancer treatment. The company, which went public on July 16, 2021, employs 145 people and is advancing a pipeline of therapies targeting liquid cancers, solid tumors, and other serious diseases. Its lead candidates, TSC-100 and TSC-101, are in clinical development for hematologic malignancies, while it also develops multiplexed TCR-T therapies and maintains an ImmunoBank of solid tumor targets across various HLA types. TScan Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TScan Therapeutics stock

FCF Conversion Rate (FCF/EBITDA) of TScan Therapeutics is 107.68 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of TScan Therapeutics changed from 89.92 % to 107.68 %, representing a 19.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) TScan Therapeutics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s TScan Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — TScan Therapeutics

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — TScan Therapeutics